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Abstract
Purpose/Objectives
To investigate pN1 prostate cancer (PCa) patients treated surgically without immediate
adjuvant treatment.
Materials and Methods
We analyzed the database of 2316 patients at our institution who underwent robot-assisted
radical prostatectomy (RARP)/radical prostatectomy (RP) between July 2005 and Novem-
ber 2012. 87 patients with pN1 PCa and received no neoadjuvant and immediate adjuvant
therapy were included in the study. Included pN1 PCa patients were followed up for median
of 60 months. Biochemical recurrence (BCR)-free survival, metastasis-free survival (MFS),
cancer specific survival (CSS), and overall survival (OS) rates were determined by using
Kaplan-Meier analysis. Cox regression analysis was performed to investigate the impact of
prostate-specific antigen (PSA) level, Gleason score, extraprostatic extension, seminal ves-
icle invasion, perineural invasion, lymphovascular invasion, positive surgical margin, tumor
volume, early post-operative PSA(6 weeks), PSA nadir, lymph node yield, and number of
pathologically positive lymph nodes on survival.
Results
The 5-year OS rate of patients was 86.1%, while the CSS rate was 89.6%. The metastasis-
free and BCR-free survival rates were 71% and 19.1%, respectively, and each was signifi-
cantly correlated with the number of positive lymph nodes on log rank tests (p = 0.004 and
p = 0.039, respectively). The presence of 2 or more pathologically positive LNs (HR:2.20;
95% CI 1.30–3.72; p = 0.003) and a Gleason score8 (HR: 2.40;95% CI: 1.32–4.38; p =
0.04) were significant negative predictors of BCR free survival on multivariable regression
analysis. Furthermore, the presence of 2 or more positive lymph nodes (HR: 1.06; 95% CI
1.01–1.11; p = 0.029) were significant negative predictors of metastasis-free survival on
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multivariable regression analysis. Additionally, in the patients who had no BCR without
adjuvant treatment 9 patients out of 10 (90%) had single positive LN and 5 patients out of 10
(50%) had Gleason score 7. Therefore, single positive LN, and Gleason scores7 have
significantly low risk of disease progression.
Conclusions
pN1 PCa patients have heterogenous clinical courses. Patients with single positive LN, and
Gleason scores7 have low risk of recurrence. Close observation with delayed adjuvant
hormone therapy can be considered in these patients.
Introduction
In prostate cancer (PCa) patients, the intraoperative diagnosis of lymph node (LN) metastasis
had been lead to the abandonment of prostatectomy and had regarded as systemically dissemi-
nated disease associate with poor prognosis [1]. Other treatment such as external beam radio-
therapy combined with systemic androgen deprivation treatment (ADT) was used for several
decades. However, with emerging evidence, recent guidelines have recommended radical pros-
tatectomy (RP) and robot-assisted radical prostatectomy (RARP) with extended pelvic LN dis-
section (ePLND) as a treatment modality in patients with high risk and very high risk PCa in
the context of multimodal treatment [2, 3]. PCa with pathologically positive LNs (pN1) had
been thought to have poorer prognosis than LN-negative PCa [4]. Nevertheless, pN1 PCa
patients had variable long-term survival outcomes, and some patients with delayed postopera-
tive treatment had no biochemical recurrence (BCR) or clinical progression, suggesting that
immediate ADT is unnecessary in some pN1 PCa patients. We investigated pN1 PCa patients
who diagnosed after RP/RARP with PLND but did not receive immediate adjuvant treatment.
The aim of this study was to evaluate the possible factors that predict recurrence in patients
with pN1 PCa.
Materials and Methods
Study patients
After obtaining institutional review board approval by human research protection center, sev-
erance hospital yonsei university health system (2014-0091-001), the patient records/informa-
tion was anonymized and de-identified prior to analysis. We analyzed the data of 2316 patients
at our institution who underwent RARP/ RP between July 2005 and November 2012. From
this cohort, 124 (5.3%) patients with pN1 PCa with no distant metastases were identified. We
excluded 17 patients who underwent neoadjuvant hormone treatment and 16 who underwent
immediate adjuvant hormone treatment and 4 patients who underwent immediate adjuvant
radiation therapy. Thus, 87 patients were ultimately included in the study.
All the patients were preoperatively evaluated by using chest radiography, abdominal/pelvic
computed tomography, prostate magnetic resonance imaging, and whole body bone scanning
according to their physicians’ discretion. BCR was defined as prostate serum antigen (PSA) lev-
els>0.2 ng/mL with secondary confirmatory increase at least 6 weeks after surgery.
Patients with low and intermediate risk localized PCa and life expectancy over 10 year were
decided to perform RARP/RP. Furthermore, patients with selected high risk and very high risk
localized PCa were decided to perform RARP/RP in the context of multimodality treatment.
Patients underwent RARP/RP with PLND and surgery was carried out by three surgeons.
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assisted radical prostatectomy; OS, Overall survival;
CSS, Cancer specific survival.
Clinical assessment
RARP was performed using a transperitoneal approach. Decision to perform ePLND was
based on the risk of lymph node metastases.The high risk and very high risk prostate cancer
patients who have probability of lymph node invasion over 4% underwent ePLND, and the
intermediate risk prostate cancer patients have underwent standard PLND (sPLND) [5, 6].
The boundaries of sPLND included the the external iliac and obturator LNs, whereas the
boundaries of ePLND additionally included the internal iliac, presacral, and common iliac LNs
up to the ureteric crossing [7]. All LN specimens were serially sectioned at 3 mm, fixed in 10%
neutral buffered formalin, and embedded in paraffin blocks. Each cut was stained with hema-
toxylin and eosin, and examined microscopically for the presence of cancer cells by a single
genitourinary pathologist with>15 years of experience.
In our study patients didn’t receive immediate adjuvant treatment either ADT or radiother-
apy. Currently, the indication of ADT or radiotherapy on pN1 PCa was not established. Some
center recommended cut off value of PSA> 5ng/mL for ADT or radiotherapy [8]. In this
study, the indication of ADT or radiotherapy was PSA> 2ng/mL or appearance of significant
symptoms (Bone or visceral metastasis, pain, hydronephrosis, bladder outlet obstruction, or
gross hematuria).
All patients included in this study had complete clinical and pathological data available,
including age, pre-operative PSA, early post-operative PSA (6 weeks), clinical and pathological
stages (according to the 2002 American Joint Committee on Cancer staging system), pathologi-
cal Gleason score, surgical margin status, tumor volume, the number of LNs removed, and the
number of positive LNs. Patients were followed-up with physical examinations and PSA mea-
surements every 6 weeks~3 months during the first year after surgery, every 6 months during
the second year, and annually thereafter.
Statistical analysis
Kaplan-Meier analysis was performed to investigate BCR-free survival, metastasis-free survival
(MFS), cancer specific survival (CSS), and overall survival (OS) rates after surgery for a median
follow-up period of 60 months. Location of recurrence and time to recurrence were analyzed.
Cause and time of death were identified from death certificates and medical records in the
database of the National Cancer Registry Center. Univariable and multivariable Cox propor-
tional regression analyses were performed to investigate the predictive factors for BCR and
metastasis after RARP/RP.
Continuous variables were presented as median and interquartile range (IQR) values. The
log-rank test was employed to evaluate subgroup survival rates. Cox proportional regression
analyses were performed to derive the predictive factors for BCR and metastasis after RARP/
RP. A two-tailed p value0.05 was deemed statistically significant. Analysis was performed
using the SPSS v.20.0 software (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics
Table 1 shows the clinical and pathological characteristics of the total cohort and pN1 PCa
patients. In this cohort, the median follow-up time was 60 months (IQR 49–69). The median
age at surgery was 67 years (IQR 62–72). Of these patients, 78 patients (89.7%) had locally
advanced PCa, 67 patients (77%) had concomitant extraprostatic extension, and 51 (58.6%)
had seminal vesicle invasion. Only 1 patient (1.1%) had a Gleason score of 6 in our cohort,
whereas a majority of 68 patients (78.1%) had Gleason scores of 8–10. From total 87 pN1
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Table 1. Clinical characteristics of total cohort and patients and pN1 prostate cancer after radical
prostatectomy/robot-assisted radical prostatectomy.
Characteristics Total Cohort, n = 2316 pN1 Patients, n = 87
Age, year, median (IQR) 65 (60–70) 67 (62–72)
BMI, kg/m2 (IQR) 24.12 (22.49–25.73) 24.33 (22.1–25.65)
ASA score category (%)
1 1413 (61) 44 (50.6)
2 871 (37.6) 42 (48.3)
3 32 (1.4) 1 (1.1)
Preoperative PSA ng/mL, median (IQR) 7.4 (5.1–12.3) 15.91 (9.18–37.91)
Early post-operative PSA ng/mL, median (IQR), 6weeks 0.01 (0.01–0.02) 0.05 (0.02–0.11)
Prostate volume, cc (IQR) 36.8 (28.2–48.4) 34 (27.2–43.3)
Tumor volume, cc (IQR) 2.5 (1–4) 6.5 (3–15)
Clinical T stage (%)
T1 810 (35) 5 (5.7)
T2 950 (41) 9 (10.3)
T3a 348 (15) 21 (24.1)
T3b 185 (8) 43 (49.4)
T4 23 (1) 9 (10.3)
Clinical N stage (%)
N0 2224 (96) 68 (78.2)
N1 92 (4) 19 (21.8)
Pathologic T stage (%)
T2 1413 (61) 9 (10.3)
T3a 718 (31) 27 (31)
T3b 162 (7) 44 (50.6)
T4 23 (1) 7 (8.1)
Pathologic Gleason score (%)6 695 (30) 1 (1.1)
7 1135 (49) 18 (20.8)
8 255 (11) 20 (23)
9 224 (9.7) 45 (51.7)
10 7 (0.3) 3 (3.4)
Extraprostatic extension (%) 853 (36.8) 67 (77)
Seminal vesicle invasion (%) 185 (8) 51 (58.6)
Positive surgical margin (%) 797 (34.4) 57 (65.5)
PSA nadir (ng/mL), median (IQR) 0.01 (0.01–0.02) 0.03 (0.01–0.26)
Time to PSA nadir (month),median (IQR) 2 (1–3) 2 (1–3)
Lymph node yield, median (IQR) 21 (16–29)
Number of positive lymph node (%)
Mean (median) 3.07 (2)
Range 1–18
1 35 (40.2)
2 20 (24.1)
3 13 (14.9)
4 5 (5.7)
5 14 (16.1)
ASA = American Society of Anesthesiologists; PSA = prostate-speciﬁc antigen; IQR = interquartile range.
doi:10.1371/journal.pone.0152391.t001
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patients, 19 patients (21.8%) had clinically positive lymphadenopathy on preoperative image.
The median number of LNs removed was 21 (IQR 16–29). Of the 87 patients, 35 patients
(40.2%) had 1 positive LN, 20 patients (24.1%) had 2 positive LN, and 32 patients (36.8%) had
3 or more pathologically positive LNs. The highest number of positive LNs in a patient was 18.
The positive surgical margin rate was 65.5% in our cohort.
Oncological outcomes
The 5-year OS rate of the patients was 86.1% (95% confidence interval [CI], 81–95) and the
CSS rate in the was 89.6% (95% CI, 83–97). The 5-year MFS and BCR-free survival rates were
71% (95% CI, 74–88) and 19.1% (95% CI, 18–31), respectively. The patients without BCR nei-
ther clinical progression was detailed in Table 2. From 16 patients of BCR-free, 10 patients
(11.5%) had no adjuvant treatment for the total follow up period. The 10 patients with BCR-
free and no adjuvant treatment patients had single positive lymph node except for just one
patient. Clinical stage N0 was found in 9 patients and only 1 patient had cN1. For Gleason
score distribution, Gleason 7 was 4 patients, for Gleason 8 was 4 patients, and Gleason 9 for 2
patients.
After median follow up of 60 months, in single positive lymph node patients, 3 patients died
due to prostate cancer, 6 patients had clinical progression of metastasis, and 20 patients had
BCR and 16 patients remained with no recurrence (biochemical and clinical). However, in 2 or
over 2 lymph node positive patients, 9 patients had died due to prostate cancer, 22 patients had
Table 2. Characteristics of pN1 PCa patients with no immediate recurrence.
Patient Age,
year
Preoperative
PSA ng/mL
Clinical
TNM
stage
Pathologic
Gleason
score
Extraprostatic
extension
Seminal
vesicle
invasion
Surgical
margin
PLND
type
Lymph
node
yield
Number
of
positive
lymph
node
Adjuvant
treatment
1 64 52.9 T3aN0M0 4+4 (+) (+) (-) ePLND 21 2 (-)
2 69 10.04 T3aN0M0 4+3 (+) (-) (-) ePLND 18 2 ADT 24 month
3 73 17.12 T3aN0M0 4+3 (+) (-) (+) ePLND 29 1 (-)
4 69 32.63 T2cN0M0 4+3 (+) (-) (-) sPLND 16 1 (-)
5 68 7.04 T3aN0M0 4+4 (+) (+) (-) sPLND 19 1 (-)
6 59 6.21 T2bN0M0 3+4 (+) (+) (-) ePLND 28 1 (-)
7 69 22.2 T3bN0M0 3+4 (+) (-) (-) ePLND 47 1 ADT
42 month
8 69 5.68 T3aN0M0 4+3 (+) (-) (+) ePLND 25 2 RT 36month
ADT 60 month
9 55 19.71 T2cN0M0 5+5 (-) (-) (-) ePLND 19 1 RT,ADT 36
month
10 67 37.91 T3bN0M0 5+4 (-) (-) (+) ePLND 24 3 ADT 36 month
11 62 11.89 T3aN0M0 4+5 (-) (+) (+) ePLND 15 1 (-)
12 78 6.39 T1cN0M0 4+3 (-) (-) (-) sPLND 12 1 (-)
13 81 76.43 T3aN0M0 4+3 (+) (-) (-) ePLND 19 2 ADT 24month
14 58 6.79 T3bN0M0 4+3 (-) (+) (+) ePLND 28 1 (-)
15 68 9.87 T3bN1M0 5+4 (-) (+) (+) sPLND 11 1 (-)
16 69 13.81 T3bN0M0 4+4 (+) (-) (-) ePLND 25 1 (-)
ADT = androgen deprivation treatment; RT = radiation treatment; sPLND = standard pelvic lymph node dissection; ePLND = extended pelvic lymph node
dissection.
doi:10.1371/journal.pone.0152391.t002
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clinical progression of metastasis, and 44 patients had asymptomatic PSA increase and just 8
patients remained with no recurrence (biochemical and clinical).
Overall 16 patients have expired. Four patients have been dead not related to prostate can-
cer, related with ischemic heart disease, COPD, and other malignancy. Of these 4 patients, 1
patient was disease free, 1 patient had only BCR, and other 2 patients had clinical progression
with bone metastasis.
There was a significant difference between each of the BCR-free rates, MFS and the number
of positive LNs (One positive LN vs two or more positive LN) as determined by log rank tests
(p = 0.004 and p = 0.039, respectively) (Fig 1). The BCR-free survival rate was also significantly
higher in patients with Gleason scores7 than in those with Gleason scores8 (20.7% vs.
14.3% respectively, p = 0.005).
Nineteen patients (21.8%) had local recurrence in the prostatic bed, 14 patients (16.1%) had
recurrence in pelvic lymph node. From patients of either local recurrence or pelvic lymph node
Fig 1. Kaplan-Meier curve for biochemical recurrence-free survival andmetastasis-free survival by
the number of positive lymph nodes. Blue line = one positive lymph node; green line = two or more positive
lymph nodes.
doi:10.1371/journal.pone.0152391.g001
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recurrence, 25 patients had recurrence with bone or visceral metastases. Only 4 patients had
exclusive local recurrence and no exclusive recurrence in pelvic lymph node. From the total
clinical recurrence patients, the 25 patients (78.1%) had bone or concomitant visceral metasta-
sis (3 patients of lung metastasis, 3 patients of liver metastasis). From total 25 metastasis
patients, 17 patients (68%) were still alive after distant metastasis.
The presence of 2 or more pathologically positive LNs (HR: 2.20; 95% CI 1.30–3.72;
p = 0.003) and a Gleason score8 (HR: 2.40; 95% CI: 1.32–4.38; p = 0.04) were significant neg-
ative predictors of BCR-free survival on Cox proportional hazard multivariable regression
analysis (Table 3). Furthermore, the presence of 2 or more positive lymph nodes (HR: 1.06;
95% CI 1.01–1.11; p = 0.029) were significant negative predictors of metastasis-free survival on
Cox proportional hazard multivariable regression analysis (Table 4). Table 5 shows the con-
temporary reports on oncologic results of pN1 PCa. In the patients who had no BCR without
adjuvant treatment, 9 patients out of 10 (90%) had single positive LN and 5 patients out of 10
(50%) had Gleason score 7.
Discussion
In this study, we investigated the role of RP/RARP with PLND in pN1 PCa patients by deter-
mining the oncological outcomes as assessed by BCR and MFS rates in pure Asian cohort.
Included patients in our study had relatively higher Gleason score PCa compared with Ameri-
can and European researches [9, 10]. Patients of pN1 PCa who underwent RP/RARP with
PLND and without adjuvant treatment had a 19.1% chance of remaining BCR-free during the
5-year follow up, as well as a 71% chance of remaining metastasis-free. Similar with western
researches, the number of positive LNs and Gleason scores were significantly related with
BCR-free survival, MFS rate.
In previous study, Boorjian et al. reported on the long term RP outcome of pN1 PCa. The
10-yr CSS was 85.8% with 89.7% of patients receiving adjuvant ADT [4]. In another study of
pN1 PCa patients who did not receive adjuvant ADT, the 7-yr BCR-free rate was 10.9% [11].
Table 3. Cox proportional hazard regression analysis of predictive factors associated with biochemical recurrence after surgical treatment with
pN1 prostate cancer patients.
Biochemical recurrence Univariable (unadjusted HR) Multivariable (adjusted HR)
Predictive factor HR 95% CI P- value HR 95% CI P- value
PSA 1.00 0.99–1.01 0.968
Pathologic Gleason score 8 2.19 1.21–3.97 0.01 2.40 1.32–4.38 0.004
Lymphovascular invasion 1.08 0.64–1.82 0.77
Perineural invasion 1.88 0.92–3.84 0.081 1.06 0.60–1.87 0.835
Extracapsular invasion 1.26 0.67–2.37 0.463
Seminal vesicle invasion 1.35 0.81–2.23 0.248
Positive surgical margin 1.51 0.88–2.57 0.135
Tumor volume 1.02 0.99–1.05 0.317
PSA nadir 1.02 0.91–1.13 0.79
Early PSA persistencePSA0.1 ng/ml at 6 weeks after surgery 1.10 0.60–2.01 0.76
Lymph node yield 1.00 0.97–1.02 0.852
Positive lymph node, no.
1 (reference) Ref Ref Ref Ref Ref Ref
2 1.94 1.15–3.26 0.012 2.20 1.30–3.72 0.003
HR = hazard ratio; CI = conﬁdence interval; PSA = prostate-speciﬁc antigen; ref = reference.
doi:10.1371/journal.pone.0152391.t003
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The clinical course of pN1 PCa is not all lethal and it is heterogeneous. It can be associated
with no clinical progression even in the absence of adjuvant treatment. We have found that2
positive LNs significantly increase the risk of BCR and metastasis, as does a Gleason score8
in BCR. Thus, the clinical outcomes vary in pN1 PCa patient populations according to the pos-
itive LN burden and the Gleason score. On detail analysis of 10 patients who were surgically
cured without BCR and had no adjuvant therapy, only 1 patient had 2 positive LNs. While the
other 9 patients had single positive LN. The patients with microscopic metastatic deposit of LN
such as this single positive LN patients had a chance for no adjuvant treatment. The number of
diseased lymph node of2 had deleterious impact on BCR and metastasis.
Few studies were investigated to assess the efficacy of no adjuvant treatment in patients with
pN1 PCa after surgical treatment. Touijer et al.[9] have investigated 369 pN1 PCa patients who
Table 5. Comparison of contemporary reports on oncologic results of pN1 prostate cancer.
Series Year Method of
operation
pN1
cases, n
Median follow up
(months)
LN yield
Median (IQR)
Survival
Spiess et al.
[8]
2007 RP 100 62 11 (3–32) 5yr BCRFS 50%; 5yr PFS 84%; 10yr PFS 69%; 5yr CSS
94%; 10yr CSS 75%
Touijer et al.
[9]
2014 RP 369 48 15 (10–21) 5yr BCRFS 54%; 10yr BCRFS 35%; 5yr PFS 79%; 10yr
PFS 65%; 5yr CSS 94%; 10yr CSS 72%
Seiler et al.
[10]
2014 RP 88 187 21 (6–41) 10yr BCRFS 8%; 10yr PFS 26%; 10yr CSS58%
Nini et al.[12] 2015 RP 800 76 19 (13–26) 5yr BCRFS 53.7%; 5yr PFS 50.5%; 5yr CSS 58.8%
Moschini
et al.[13]
2015 RP 1011 211 13 (9–18) 15yr BCRFS 34.1%; 15yr PFS 67%; 15yr CSS 20%
Current study 2016 RP/RARP 87 60 21 (16–29) 5yr BCRFS 19.1%; 5yr PFS 71%; 5yr CSS 89.6%
BCRFS = Biochemical recurrence rate free survival; PFS = Progression free survival; CSS = Cancer-speciﬁc survival; OS = Overall survival; RP = Radical
prostatectomy; RARP = Robot-assisted radical prostatectomy.
doi:10.1371/journal.pone.0152391.t005
Table 4. Cox proportional hazard regression analysis of predictive factors associated with distant metastasis after surgical treatment with pN1
prostate cancer patients.
Distant metastasis Univariable (unadjusted HR) Multivariable (adjusted HR)
Predictive factor HR 95% CI P- value HR 95% CI P- value
PSA 1.01 0.99–1.02 0.728
Pathologic Gleason score 8 1.05 0.31–3.56 0.934
Lymphovascular invasion 1.82 0.82–4.08 0.094 1.93 0.86–4.37 0.115
Perineural invasion 0.58 0.17–1.98 0.384
Extracapsular invasion 1.49 0.56–3.97 0.426
Seminal vesicle invasion 0.94 0.44–2.01 0.875
Positive surgical margin 1.27 0.54–2.99 0.587
Tumor volume 1.04 0.98–1.10 0.206
PSA nadir 0.94 0.69–1.29 0.716
Early PSA persistence
PSA0.1 ng/ml at 6 weeks after surgery
0.83 0.34–2.07 0.831
Lymph node yield 0.77 0.31–1.93 0.576
Positive lymph node, no.
1 (reference) Ref Ref Ref Ref Ref Ref
2 1.05 1.01–1.10 0.034 1.06 1.01–1.11 0.029
HR = hazard ratio; CI = conﬁdence interval; PSA = prostate-speciﬁc antigen; Ref = reference.
doi:10.1371/journal.pone.0152391.t004
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underwent RP and ePLND with no adjuvant treatment at a median follow up of 48 months.
The predicted 10-yr BCR free survival, and MFS rates were 28%, and 65%, respectively. The
10-yr OS, and CSS rates were 60%, and 72%, respectively. Predictors of BCR risk were Gleason
score>7, positive surgical margin and3 positive LNs. Additionally, Seiler et al. [10] have inves-
tigated the long-term oncological result of 88 patients with pN1 PCa who underwent RP and
PLND with a median follow up of 15.6 years. The number of positive nodes was the significant
prognostic factor for CSS since patients with2positive nodes had a threefold greater risk of can-
cer specific death. The 10-yr OS and CSS were 51%, 58%, respectively. Comparing the oncologic
outcome between 1 positive LN group and2positive LN group, incidence of BCR free survival
was 18% in 1 positive LN group, 54% of patients showed clinical progression and 31% died of
PCa. However,2 positive LN group revealed 0% of BCR free survival within 10 years, only 10%
had clinically progression-free survival, and two-thirds of patients have died of PCa.
In terms of clinical recurrence pattern on pN1 PCa, Nini et al [12] have investigated 800 pN1
PCa who underwent RP and ePLNDwith a median follow-up of 76 months. One-third of patients
with pN1 PCa experienced clinical recurrence and from those patients, one-third had local or
nodal recurrence. Experiencing local or nodal recurrence had higher 5-yr CSS rates compared
with those of reptroperitoneal nodal, skeletal, and visceral recurrence. The site of recurrence (skel-
etal, visceral), pathologic gradepT3b, pathologic Glesason score 9–10 were independent predic-
tor of CSS. Moschini et al.[13] investigated the natural history of 1011 pN1 PCa patients with a
median follow-up of 211 months. Nearly all patients received adjuvant ADT and adjuvant radia-
tion treatment (aRT) was given based on patient discretion. The 15-yr clinical recurrence rate was
33%. The solitary locations were skeletal (55%), nodal (34%), local soft tissue (17%), and visceral
(5%). Predictors for clinical recurrence were Gleason score 8–10, number of positive nodes, and
more recent year of surgery. The 15yr CSS after clinical recurrence was 20%. Multiple recurrences,
skeletal, and visceral metastases were significantly associated with CSS. (Table 5)
In our study, the clinical recurrence with no immediate adjuvant treatment cohort, only 4
patients (4.6%) had exclusive pelvic local recurrence, and no patient had exclusive pelvic LN
recurrence. Furthermore, eventually 25 patients (28.7%) had bone or concomitant visceral
metastases. The patients who showed clinical progression in pN1 PCa, had higher rate of dis-
tant metastasis. Therefore, systemic ADT rather than local radiation therapy could be consid-
ered in the setting of adjuvant therapy for higher burden positive LNs
According to current guidelines, ePLND is recommended in patients with a high risk of LN
metastasis [2]. Recently, the use of RARP as sharply risen while PLND have been decreased,
even in patients with high-risk PCa, because of the technically challenging and time consuming
aspects of the procedure, especially with the advent of robotics [14]. However, for intermedi-
ate- and high-risk PCa patients, PLND is critical for tumor control and survival due to the fact
that it eliminates the chance of micrometastases.
Positive LNs after RP were uncommon and decreased over the last 30-years with the inci-
dence of 8.3%, 3.5%, and 1.4% based on pre, early, and contemporary PSA eras [15]. Since the
recent introduction of robotics, the clinical course after RARP in pN1 PCa has not been investi-
gated [16]. BCR and metastasis after surgical treatment of pN1 PCa remains an issue of con-
cern in robotic era, even though not all patients with pN1 PCa develop BCR or metastasis.
In the past, pN1 PCa was considered a poor prognostic factor associated with a limited
chance of cure and poor long-term survival regardless of treatment modality. Although the
multimodal approaches involving surgical, radiological, and hormone treatments have shown
to be beneficial. However, the optimal standard management has not been clearly established
yet. The majority of patients with pN1 PCa receive ADT after surgery, however, the indication
and timing of ADT vary among clinicians. Several studies have investigated the survival benefit
of surgical management of pN1 PCa over hormone treatment alone [17]. Messing et al.
Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence
PLOS ONE | DOI:10.1371/journal.pone.0152391 March 31, 2016 9 / 11
concluded that immediate adjuvant ADT after RP and PLND improved the survival of pN1
PCa patients, since 77% of patients who received immediate ADT were alive and had no evi-
dence of recurrent disease, including undetectable serum PSA levels compared to 18% of
patients who did not receive ADT after sugery[18].
As some pN1 PCa patients experienced long-term BCR-free and progression-free status,
accurate identification of those patients with pN1 PCa who will benefit from immediate ADT
is critical. Furthermore, evidence suggests that the timing of ADT should be adapted for each
individual according to the risk of clinical progression, as the optimal timing and indication of
adjuvant ADT in pN1 PCa is still a matter of debate [18].
Patients with low LN burdens (single positive LN), and a low Gleason scores (7) could be
able to defer immediate adjuvant ADT because of the low risk of BCR and clinical progression.
Spiess et al. suggested that ADT can be delayed until BCR, indicated by PSA>5 ng/mL, with-
out impairing the oncologic outcome [8]. Delaying adjuvant ADT in selected pN1 PCa patients
has some advantages. First, it restricts adjuvant ADT only to high risk patients of clinical pro-
gression after surgery. Second, it avoids related side effect such as hot flashes, osteoporosis, and
muscle loss. Third, it prevents overtreatment and saves treatment costs. Therefore, immediate
ADT should not be routinely offered to patients who have a minimal metastatic burden. It
seems that patients with increased number of positive LNs may be benefit from extended tem-
plates, while patients with a lower positive LN burden may have better prognosis. Moreover,
the PCa with Gleason scores7 has low aggressiveness, and less clinical progression.
In our study, we had a median follow up of 60 months which was not enough for evaluation
of the long-term clinical recurrence course or death due to the new introduction of robotics
system. However, we could evaluate recent era by including pN1 PCa cases who underwent
both of RP and RARP. In addition, we investigated individual aspects of cases with neither clin-
ical recurrence nor BCR, and the majority of cases revealed single positive LN. We excluded
patients who received neoadjuvant or immediate adjuvant therapy. Therefore, we could select
and predict with no recurred cases of pN1 PCa.
Our study contains certain limitations. First, it is a retrospective study, and thus contains
inherent selection biases towards patients who underwent a particular surgical technique. Sec-
ond, the median follow-up period of 60 months for our cohort was short to assess the long-
term recurrence patterns and survival rates for PCa in robotic era. Third, the PLND template
varied according to individual patient`s LN invasion risk and surgeon preference, however,
median LN yield was 21 which was comparable with ePLND cases. Despite these limitations,
the novelty of our study is clear in the fact that it is the first Asian oncological investigation and
individual analysis for identification of pN1 PCa patients who could be treated by surgery
alone without the need of immediate adjuvant therapy.
Conclusions
Patients with single positive LN and Gleason scores7 have chance of no recurrence after sur-
gical treatment. Close observation with delayed adjuvant hormone therapy can be considered
in those patients. Additionally, the majority of pN1 PCa who revealed clinical progression had
distant metastasis. Therefore, systemic adjuvant ADT could be considered with patients who
have high LN burden2.
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